财务数据和关键指标变化 - 第一季度合作收入为1450万美元,同比增长39%,主要由于YUPELRI销售净额增长和运营利润率改善 [31] - 公司现金储备为1亿美元,约4860万股股票流通在外 [32] YUPELRI业务表现 - YUPELRI第一季度销售净额为5520万美元,同比增长18% [17] - 医院渠道销量同比增长31%,创历史新高 [19][20][21] - 医院市场份额稳定在16.6%,4月份已增至约18% [22] - 社区市场份额维持在31%左右 [22] - 零售渠道处方量下降9%,新开处方下降3%,可能受到Change Healthcare网络事故影响 [23][24][25] - 公司有望获得250万美元销售里程碑,以及中国上市后的750万美元里程碑和14%-20%的销售提成 [28] Ampreloxetine项目进展 - 正在加快CYPRESS III期注册试验的患者入组,预计下半年完成入组 [12][13][14] - 正在为NDA申报做准备工作,将尽快在CYPRESS结果公布后提交 [13] - 5月23日将举办投资者活动,介绍Ampreloxetine在治疗多系统萎缩症伴症状性神经性低血压的科学依据和机会 [15] 三联疗法里程碑 - 三联疗法第一季度销售达7.49亿美元,同比增长32% [33] - 预计2024年可获得至少2500万美元里程碑,2025-2026年可获得多达1亿美元里程碑 [34][35] 公司战略和发展方向 - 公司将继续与Viatris合作推动YUPELRI在美国和中国的增长 [37] - 将专注于Ampreloxetine的临床开发和商业化准备 [37] - 公司有1亿美元现金储备,无债务,有望获得近期里程碑,资金状况良好 [38]

Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update DUBLIN, IRELAND – MAY 13, 2024 – Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the first quarter of 2024. "Building on recent momentum, the Theravance commercial team again delivered a solid quarter of YUPELRI hospital sales execution in the first quarter, setting us on a path to contribute significantly ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033 THERAVANCE BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Cayman Islands 98-1226628 (Sta ...

Theravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2023 Earnings Conference Call February 26, 2024 5:00 PM ET Â Company Participants Rick Winningham - Chief Executive Officer Aine Miller - Head, Development Rhonda Farnum - Chief Business Officer Aziz Sawaf - Chief Financial Officer Conference Call Participants Douglas Tsao - H.C. Wainwright David Risinger - Leerink Partners Eva Privitera - Cowen Julian Harrison - BTIG Operator Ladies and gentlemen, good afternoon. IÂ'd like to welcome everyone to the Theravance Bi ...

Forward Looking Statements Non-GAAP Financial Measures 2 3 Ampreloxetine | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | | | | | | | | | | Fourth Quarter & Full Year 2023 ...

Exhibit 99.1 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update DUBLIN, IRELAND – FEB 26, 2024 – Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced financial and operational results for the fourth quarter of 2023 and full-year ended December 31, 2023. "The Theravance team delivered a strong performance in 2023, having achieved our financial objectives in the fourth quarter and exceeded our aggre ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98 ...

To conclude, on slide 23, I'll provide an update on our potential to earn milestones on global net sales of TRELEGY. GSK delivered another strong quarter of growth with quarterly and year-to-date net sales reaching $675 million and $2 billion respectively, up 22% and 25% when compared to the same period a year ago. To achieve our first $50 million milestone in 2023, TRELEGY would need to re-examine its net sales to reach $2.9 billion for the year, which based on the Q3 results we now believe is unlikely. Ri ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36033 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 98-1226 ...

related to guidance. We're slightly below for R&D and slightly above, but all within the ranges that we've provided before. So hopefully, that provides a bit of color for you, David. David Risinger Operator I think that -- go ahead, Aziz. So Rhonda, do you have any additional comments there? And then just one final question. Now that the PIFR-2 readout is really sort of getting close, how should we think, if we get the outcome that we expect to get -- how should we think about that? Or how -- what's the sor ...